RECEIVED CENTRAL FAX CENTER APR 2 4 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/740,263

Filed:

12/18/2003

For:

CREATINE SALTS

AND METHOD OF MAKING SAME

Art Unit:

1621

Examiner:

Price, Elvis O.

Atty Dkt.:

84-03

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. §1.131

Sir:

I, Matthias Boldt, do hereby declare the following:

- 1) I am the named inventor of the above-identified patent application.
- I have read and understand the present application including the claims as originally filed.
- I have read and understand the Office Action dated December 22, 2005 in connection with the present application.
- 4) In the office action, claims 1-13 stand as rejected under 35 U.S.C. 103(a) as being unpatentable over Negrisoli, et. al. (U.S. Patent No. 5,973.199 in view of Llewellyn, U.S. Patent Publication No. 2004/0077902, filed October 18, 2002.

Certificate of FACSIMILE TRANSMISSION

DATE OF DEPOSIT
J-24-96
LHEREBY CERTIFY THAT THIS PAPER IS

THEREBY CREDBY THAT THIS PAUGEDS
BEING SIEN, VIA FACSIMILE
TRANSMISSION
ON THE DATE WOLLD TROPE FAD IS
ADDRESSED TO:
COMMISSIONER OF PATENTS, P.O. ROL
LANDAL STRANGE, VA. 22312

Frank.

JOSEPH E. CHOVANES

ı

- I have read and understand the Negrisoli and Llewellyn references, and the corresponding rejections based on those references.
- 6) The inventions set forth in claims 1-13 of the present application were both conceived and reduced to practice in this country or in a NAFTA or WTO member country at least as early as May 6, 2002, which is well before the priority date of Llewellyn (October 18, 2002.)
- 7) Conception occurred at least as early as February 25, 2002, when I discussed various embodiments, including both di- and tri-creatine embodiments, with a contract laboratory.
- It should also be noted that there was due diligence from conception to the subsequent reduction to practice.
- An example of reduction to practice of the inventions according to the claims is illustrated in Exhibit 1 attached hereto, and dated May 6, 2002.
- 10) Exhibit 1 is a fax, received by the assignee of the present application, and showing a tri-creatine embodiment has been shipped from the contract laboratory, and was available for our receipt as of May 6, 2002.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and thus such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:	
	Matthias Boldt




EXHIBIT A To DECLARATION OF MATTHIAS BOLDT

100/100@

01\58\500¢ 15 38 EVX